** Analysts at Jefferies see New Zealand's Fisher & Paykel Healthcare FPH.NZ mitigating impact of 25% U.S. tariffs on Mexican imports

** Brokerage upgrades the medical equipment maker to "buy" from "hold", raises price target to NZ$39.40 from NZ$35.25

** "FPH's New Zealand-manufactured products already FDA approved, the option to substitute Mexican with NZ imports is only limited by re-routing and freight lead times," Jefferies says

** Adds that FPH's three months of inventory available in the U.S. and potential to increase prices will help further moderate the impact of tariffs in FY26

** Two of 12 analysts rate the stock "buy", seven "hold" and three "sell" or lower; their median PT is NZ$37.00 – LSEG data

** Stock closed at NZ$34.5 on Tuesday, down 10.2% YTD

(Reporting by Aaditya Govind Rao in Bengaluru)

((Aaditya.govindrao@thomsonreuters.com;))